Recombinant Human VEGF Receptors binding domains & Fc fragment Region (human IgG1) Protein

Artikelnummer: ABB-YR0066
Artikelname: Recombinant Human VEGF Receptors binding domains & Fc fragment Region (human IgG1) Protein
Artikelnummer: ABB-YR0066
Hersteller Artikelnummer: YR0066
Alternativnummer: ABB-YR0066-20MG,ABB-YR0066-5MG,ABB-YR0066-1MG
Hersteller: ABclonal
Kategorie: Antikörper
Applikation: ELISA, NeA
Immunogen: /
Alternative Synonym: VPF, VEGFA, MVCD1, L-VEGF
What is research grade Aflibercept biosimilar? Research grade Aflibercept biosimilar has the same amino acid sequence as Aflibercept (trade name Eylea), a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). It inhibits vascular endothelial growth factor (VEGF), and is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Aflibercept is a dimeric glycoprotein with a molecular weight of 96.9 kilo Daltons (kDa). Glycosylation adds its molecular weight to 115 kDa in total. Ziv-aflibercept (trade name Zaltrap) was developed as an injection for treatment of metastatic colorectal cancer.
NCBI: 7422
UniProt: P15692
Reinheit: >95% Determined by SDS-PAGE
Target-Kategorie: VEGF
Application Verdünnung: In Vivo Grade Recombinant Human IgG1 Fc Protein
Anwendungsbeschreibung: Cross-Reactivity: <1EU/mg (<0.001EU/µg)Determined by LAL gel clotting assay. ResearchArea: Cancer immunology